Article ; Online: Antifibrotic action of Yifei Sanjie formula enhanced autophagy via PI3K-AKT-mTOR signaling pathway in mouse model of pulmonary fibrosis.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2019 Volume 118, Page(s) 109293
Abstract: ... with a high mortality rate, but its origin is unknown and there is no effective treatment. Yifei Sanjie ...
Abstract | Pulmonary fibrosis (PF) is a crippling disease characterized by progressive dyspnea and associated with a high mortality rate, but its origin is unknown and there is no effective treatment. Yifei Sanjie formula (YFSJF) is a Chinese medicine that is widely used for treatment of respiratory systems disease. However, the molecular basis for the function of YFSJF has not been determined. Here we investigate the contribution of YFSJF in BLM-induced PF mice. Administration with YFSJF significantly alleviated the degree of BLM-induced collagen I and III deposition and the inflammatory injuring in the lungs and suppressed hydroxyproline release in PF animals. The active components of YFSJF are comprised with flavonoid, amino acids, saponins, oligosaccharide, organic acid, vitamin, esters, purine nucleosides. Additionally, there was a significant increase in autophagosomes, after treatment with YFSJF in PF animals. Interestingly, autophagy dysfunction by the blocker chloroquine (CQ) resulted in collagen deposition and inducing the expression of fibrosis-related genes. In addition, YFSJF-induced autophagy is mediated by the PI3K-AKT-mTOR pathway, and knockdown of PI3K by siRNA up-regulated the expression of autophagy-related genes and down-regulated the expression of collagen in human lung fibroblasts (HLF). Our findings provide a detailed understanding that YFSJF-antifibrotic effects are mainly mediated by triggering autophagy, and suppressing phosphorylation of the PI3K-AKT-mTOR pathway is required for YFSJF-curative effect. |
---|---|
MeSH term(s) | Animals ; Autophagosomes/metabolism ; Autophagosomes/ultrastructure ; Autophagy/drug effects ; Collagen/metabolism ; Disease Models, Animal ; Drugs, Chinese Herbal ; Humans ; Inflammation/complications ; Inflammation/pathology ; Lung/pathology ; Male ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphorylation/drug effects ; Proto-Oncogene Proteins c-akt/metabolism ; Pulmonary Fibrosis/complications ; Pulmonary Fibrosis/drug therapy ; Pulmonary Fibrosis/metabolism ; Pulmonary Fibrosis/pathology ; Signal Transduction ; TOR Serine-Threonine Kinases/metabolism ; Transforming Growth Factor beta1/metabolism |
Chemical Substances | Drugs, Chinese Herbal ; Transforming Growth Factor beta1 ; Collagen (9007-34-5) ; TOR Serine-Threonine Kinases (EC 2.7.1.1) ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1) |
Language | English |
Publishing date | 2019-08-08 |
Publishing country | France |
Document type | Journal Article |
ZDB-ID | 392415-4 |
ISSN | 1950-6007 ; 0753-3322 ; 0300-0893 |
ISSN (online) | 1950-6007 |
ISSN | 0753-3322 ; 0300-0893 |
DOI | 10.1016/j.biopha.2019.109293 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ud II Zs.198: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.